 Home > Medical News > Latest Medical News > Sansheng Guojian Recombinant Anti-IL-17A Humanized Monoclonal Antibody Phase II Clinical Completion of the First Subject Enrolled

Sansheng Guojian Recombinant Anti-IL-17A Humanized Monoclonal Antibody Phase II Clinical Completion of the First Subject Enrolled

 Last Update: 2021-05-23
 Source: Internet
 Author: User

Tags

anti drug antibodies

therapeutic monoclonal antibodies

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 21, Sunshine Guojian announced that its recombinant anti-IL-17A humanized monoclonal antibody (drug code: 608) is currently conducting clinical research on the treatment of moderate to severe plaque psoriasis, namely "recombinant anti-IL Randomized, double-blind, placebo-controlled, multi-dose escalation and dose exploration safety tolerability, pharmacokinetics and safety of -17A humanized monoclonal antibody injection subcutaneously in the treatment of moderate to severe plaque psoriasis in China Phase II clinical trial of efficacy", and the enrollment of the first subject has been completed recently.

608 is the same drug with the same target as Novartis Secukinumab (Cosentyx) and Eli Lilly's Ixekizumab (Taltz), but it is a brand-new amino acid sequence.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Sansheng Guojian recombinant anti-IL-17A humanized monoclonal antibody for the treatment of moderate to severe plaque psoriasis phase II clinical trial completed the first subject to be enrolled

07-08

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Sansheng Guojian Recombinant Anti-IL-17A Humanized Monoclonal Antibody Phase II Clinical Completion of the First Subject Enrolled

Related Articles

Sansheng Guojian recombinant anti-IL-17A humanized monoclonal antibody for the treatment of moderate to severe plaque psoriasis phase II clinical trial completed the first subject to be enrolled